Treatment of Parkinson’s disease: the potential of extended-release pramipexole

February 23, 2021
1025
Resume

Given the current clinical guidelines, according to which the main goal of treatment of patients with Parkinson’s disease is to correct the deficiency of endogenous dopamine in the nigrostriatal part of the brain, the gold standard of treatment of this neurodegenerative pathology is considered to be levodopa. However, its long-term use leads to severe secondary side effects. The use of modern non-ergoline dopamine receptor agonists, which differ from levodopa in mechanism of action, may be a clinical solution for patients with motor disorders and levodopa-induced dyskinesias. Previous studies have shown the efficacy of the synthetic non-ergoline dopamine receptor agonist pramipexole as the drug of choice in the early stages of Parkinson’s disease. The advantage of using the new oral form of pramipexole with extended release is a significant reduction in the severity of clinical symptoms of motor disorders by achieving and maintaining a stable concentration of dopamine in blood plasma throughout the day. The publication is devoted to the analysis of the efficacy and safety of pramipexole both in monotherapy and in combination with levodopa, in the treatment of patients with early and late stages of the Parkinson’s disease. Particular attention is paid to the study of the effects of pramipexole on rest tremor and depressive disorders in patients with Parkinson’s disease.

References:

  • 1. Schapira A.H., Obeso J. (2006) Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Ann. Neurol., 59: 559–562. https//DOI: 10.1002/ana.20789
  • 2. Fahn S., Oakes D., Shoulson I. et al. (2004) Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med., 351: 2498–2250. https//DOI: 10.1056/NEJMoa033447
  • 3. Fahn S., Oakes D., Shoulson I. et al. (2004) Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med., 351: 2498–2250. https//DOI: 10.1056/NEJMoa033447
  • 4. Levin O.S. (2013) Pramipexol in the treatment of Parkinson’s disease: practical aspects of the extended-release form. Modern Ther. Psy-chiatr. Neurol., 2: 24–29. (In Rus.).
  • 5. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA, 284: 1931–1938. https//DOI: 10.1001/jama.284.15.1931
  • 6. Karabanov A.V., Illarioshkin S.N. (2014) Experience of using Mirapex PD in Parkinson’s disease. Nervous diseases, 23–32. (In Rus.).
  • 7. Illarioshkin S.N. (2013) Pramipexole in the early and late stages of Parkinson’s disease. Pharmateca, 13 (https://pharmateca.ru/ru/archive/article/12014). (In Rus.).
  • 8. Fox S.H., Katzenschlager R., Lim S.Y. et al. (2011) The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov. Disord., 26: S2–S41. https//doi: 10.1002/mds.23829
  • 9. Pogarell O., Gasser T., Hilten J.J. et al. (2021) Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J. Neurol. Neurosurg. Psychiatr. (http://doi.org/ 10.1136/jnnp.7).
  • 10. Hori H., Kunugi H. (2012) The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial. Scientific World J., 2012: 372474. https://doi: 10.1100/2012/372474
  • 11. Illarioshkin S.N. (2013) Possibilities of a dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease. Health of Ukraine, 4: 36–37. (In Rus.).
  • 12. https://compendium.com.ua/dec/337710
  • 13. Mizuno Y., Yamamoto M., Kuno S. et al. (2012) Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin. Neuropharmacol., 35(4): 174–181. https//doi: 10.1097/WNF.0b013e31825f77b9
  • 14. Eisenreich W., Sommer B., Hartter S., Jost W.H. (2010) Pramipexole Extended Release: A Novel Treatment Option in Parkinson’s Disease. https://www.hindawi.com/journals/pd/2010/612619/
  • 15. Rascol O., Barone P., Hauser R.A. et al. (2010) Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson’s disease. https://movementdisorders.onlinelibrary.wiley.com/doi/abs/10.1002/mds.23262
  • 16. Poewe W., Rascol O., Barone P. et al.; Pramipexole ER Studies Group (2011) Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology, 77(8): 759–766. doi: 10.1212/WNL.0b013e31822affb0
  • 17. Schapira A., Barone P., Hauser R.A. et al.; Pramipexole ER Studies Group (2009) Efficacy and safety of pramipexole extended-release for advanced Parkinson’s disease. Poster WE-199, 13th Annual International Congress of Parkinson’s Disease and Movement Disorders.
  • 18. Shen Z., Kong D. (2018) Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease. Medicine (Baltimore), 97(34): e11316. https://doi: 10.1097/MD.0000000000011316